Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2021-01-27 Share Issue/Capital Cha…
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 1% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly states the data as of December 31, 2020, referencing French regulatory articles (AMF). This content directly relates to the total number of shares and voting rights, which falls under the category of Capital/Financing Updates (CAP) or potentially a specific regulatory filing. However, given the specific nature of reporting share capital and voting rights monthly, it is a direct update on the capital structure. While 'SHA' (Share Issue/Capital Change) exists, this is a routine monthly disclosure of the current state, not an announcement of a new issue or change. The closest fit among the provided codes for routine capital structure disclosure is 'CAP' (Capital/Financing Update), although 'RNS' (Regulatory Filings) is also plausible as a general catch-all for mandatory regulatory disclosures not covered elsewhere. Since it details the composition of the capital, 'CAP' is the most specific fit for capital structure information, even if routine. Given the French context and the specific nature of this disclosure (often mandated alongside other filings), it is a specific regulatory disclosure about capital structure. I will classify it as CAP as it directly concerns the capital structure count.
2021-01-27 French
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE - 2nd SEMESTRE 2020
Fund Information / Factsheet Classification · 1% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE – 2nd SEMESTRE 2020" (Semi-annual statement of the liquidity contract - 2nd Semester 2020). It details the holdings (shares and cash) in a liquidity account managed by PORTZAMPARC for the company THERANEXUS as of December 31, 2020, and provides a detailed breakdown of transactions (purchases and sales) executed during the second half of 2020. This type of periodic report, specifically detailing the status and activity of a liquidity contract (often mandated by financial regulators like the AMF in France), is a specialized financial disclosure. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). It relates to the company's capital management and market operations, but the specific focus on the liquidity contract makes it distinct. Given the options, this document reports on specific financial/capital management activity over a defined period (semi-annual) but is not a comprehensive financial statement. It most closely aligns with a specialized report on capital/financing activities or a regulatory filing. Since it is a detailed report on the status of a liquidity contract, which is a form of capital management/market stabilization activity, 'Capital/Financing Update' (CAP) is a possibility, but 'Regulatory Filings' (RNS) is often used for specific, mandated, periodic disclosures that don't fit core financial statements. However, the content is highly specific to the liquidity contract mechanism. In the context of French market regulations, these liquidity contract reports are specific periodic disclosures. Since there isn't a perfect fit for 'Liquidity Contract Report', and it details capital/share activity over a period, 'CAP' (Capital/Financing Update) is the closest thematic fit, as liquidity contracts are financing/market stabilization tools. Given the detailed transactional data, it is a report, not just an announcement (RPA). I will classify it as CAP due to the subject matter (liquidity contract activity).
2021-01-19 French
THERANEXUS PRESENTS AN UPDATE ON THE PROGRESS OF ITS MAIN PROGRAMS AND ANNOUNCES ITS CASH POSITION AS OF 31 DECEMBER 2020
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated January 18, 2021, detailing an update on company programs (THN102 and BBDF-101) and announcing the implementation of a new equity line of up to €8.4 million with an investor (IRIS). It discusses financing activities, capital structure changes (issuance of Warrants and Bonds), and provides a future date for the next financial publication (Annual results on April 7, 2021). The core subject is a significant financing/capital structure event. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full 10-K, an earnings release (ER), or a simple dividend notice (DIV). Since it details the mechanics of raising capital, CAP is the most appropriate classification.
2021-01-18 English
THERANEXUS FAIT UN POINT SUR l'AVANCEMENT DE SES PRINCIPAUX PROGRAMMES ET ANNONCE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2020
Capital/Financing Update Classification · 1% confidence The document is a press release dated January 18, 2021, from Theranexus. It provides an update on clinical programs (THN102 and BBDF-101) and, crucially, announces the establishment of a new equity financing line ('nouvelle ligne de financement en fonds propres') of up to 8.4 million euros via the issuance of warrants (Bons) convertible into bonds (Obligations) reserved for a specific investor (IRIS). This action directly relates to the company's fundraising and capital structure management to secure funding for its growth and clinical trials. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA), as it contains substantive financial and strategic news.
2021-01-18 French
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021
Report Publication Announcement Classification · 1% confidence The document is titled "THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021" and explicitly lists future dates for key corporate events such as '2020 Year-End Results', 'Annual Shareholders Meeting', and '2021 Half-Year Results'. It also lists planned investor events. Since the document is an announcement about *when* future reports and meetings will occur, rather than being the report itself (like a 10-K or IR) or the results announcement (ER), it fits best under the category for announcing the publication or scheduling of reports. Given the options, 'Report Publication Announcement' (RPA) is the most appropriate fit, as it announces the schedule for various corporate publications and events. The document length (2753 chars) also supports the 'announcement' classification over a full report.
2020-12-28 English
THERANEXUS PUBLIE SON AGENDA FINANCIER 2021
Report Publication Announcement Classification · 1% confidence The document is titled "THERANEXUS PUBLIE SON AGENDA FINANCIER 2021" (Theranexus Publishes its 2021 Financial Calendar). It lists future dates for key corporate events such as cash position updates, annual financial results, and the Annual General Meeting (AGM). This is not the actual financial report (like 10-K or IR), nor is it a transcript or a specific regulatory filing detailing a transaction or result. Instead, it is an announcement about the schedule of future corporate publications and investor events. According to Rule 2, when a document announces the timing or publication of reports, it often falls under Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this document specifically announces the schedule for financial results, AGM, and investor participation, RPA is the most fitting category, as it announces the publication schedule for reports.
2020-12-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.